Moreover, a recent clinical trial targeting unresectable HCC composed of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) reported that increased overall survival (OS) and progression-free survival (PFS) were observed in the combined group than sorafenib alone group [11]. This evidence concerns the gene CD274 and hepatocellular carcinoma.